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Abstract
Background: Chemotherapy before resection of colorectal metastases in the liver is extensively used
and has been shown to induce histopathological changes in the liver parenchyma, although little is known
about the effect of chemotherapy on liver regeneration. The aim of this study was to determine if
pre-operative chemotherapy influences the regenerated liver volume after a major liver resection.
Patients and methods: This retrospective cohort study included 74 patients subjected to a major liver
resection for colorectal metastases. Patients were divided into two groups depending on whether they
had been treated with chemotherapy less than 3 months before surgery or not. Liver volumes were
measured before and 1 year after resection.
Results: Pre-operative chemotherapy reduced volumetric liver regeneration (83  2% versus 91  2%;
P = 0.007) as compared with patients without chemotherapy. There was a linear correlation between
regenerated volume and time interval between the end of chemotherapy to resection (P = 0.031).
Conclusions: Pre-operative chemotherapy in patients with colorectal liver metastases negatively affects
volume regeneration after a partial hepatectomy. The time interval between chemotherapy and surgery
determines the impact of these affects.
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Introduction
Colorectal cancer (CRC) is one of the most common malignancies
in the Western world and the third leading cause of cancer-related
mortality in both men and women.1 Between 30% and 50% of
patients will develop liver metastases during the course of the
disease.2,3 A resection is currently the only available potentially
curative treatment and for patients with resectable liver metas-
tases and renders a 5-year survival rate in the range of 38–58%.4–7
One of the current criteria for curative operability of CRC liver
metastases is the sparing of adequate liver volume.8 This implies a
remnant liver volume after a resection of at least 25% in healthy
livers9–11 and more than 30–40% in patients with any impairment
of liver function.11,12 Using novel treatment strategies, such as
portal vein embolization (PVE), a two-stage hepatectomy and
pre-operative chemotherapy, the number of patients who are
potential candidates for a resection has gradually increased.13–16
By decreasing the tumour size, pre-operative chemotherapy can
permit a curative resection in 15–50% of patients who initially
presented with irresectable disease.17,18 Additionally, it may extend
progression-free survival and overall survival.19,20
Pre-operative chemotherapy also has possible disadvantages.
Several previous studies have shown that chemotherapy may
induce parenchymal liver injury, such as steatosis, steatohepatitis
and a veno-occusive disease termed sinusoidal obstruction syn-
drome, all reported as predictors for post-operative complica-
tions, liver failure or worsened long-term prognosis.21–25
Moreover, pre-operative chemotherapy could reduce the hyper-
trophy of the liver after PVE.26,27
However, there is little knowledge of the impact of pre-
operative chemotherapy on liver regeneration after a major liver
resection. A healthy liver regains mass quickly, even during the
first week after a major resection, after which regeneration slowly
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declines28 stopping 6 months to 1 year after a hepatectomy.29–31
Not at least if a second or repeated hepatectomy is considered, it is
of value to evaluate the effect of pre-operative chemotherapy on
liver regeneration. The aim of this retrospective study was to assess
the influence of pre-operative chemotherapy on the regeneration
of liver volume after a major resection for CRC liver metastases.
Methods
Selection of patients
All consecutive patients with CRC liver metastases who under-
went a major hepatectomy, i.e. a resection of three or more Couin-
aud’s segments, at Skåne University Hospital, Lund, Sweden,
between 2005 and 2010, were identified. By including only resi-
dents of the region of Skåne, with a total population of 1.2
million, to ensure readily available follow-up radiology, a cohort
of 78 patients was obtained. Four patients were excluded, two
owing to death before any follow-up radiology was obtained, one
owing to reoperation for liver metastases within 6 months and
one owing to an inability to retrieve the pre-operative CT scan,
leaving 74 patients for further analysis. Patients were grouped
according to if they had (n = 34) or had not (n = 40) received
chemotherapy within 3 months before surgery.
Liver volume measurements
Pre- and post-operative liver volumes were calculated using com-
puted tomography or magnetic resonance imaging transversal
plane images. The liver contour on all image sections was manu-
ally traced and the area was automatically calculated. Each image
section area was multiplied with the section thickness (typically
5 mm) to obtain liver volume. The pre-operative images of
patients were selected on the basis of the most recent available
images prior to the operation. On PVE patients, the most recent
available images prior to PVE were selected instead. The patients
that had PVE and chemotherapy (n = 9) were embolized 1–3
weeks after interruption of chemotherapy, four patients had addi-
tional chemotherapy while awaiting a resection, which was
performed 6–10 weeks after the last chemotherapy cycle. Post-
operative images were based on images from the closest to 1 year
after the operation. No post-operative images closer than 6
months from the operation were selected. Metastasis volume was
measured in the same way as liver volume measurement and then
subtracted from the liver volume to get the functional liver
volume (FLV). The %FLVpost/pre-op was defined as the ratio of post-
and preoperative FLV. Percentage values over 100 represent a
larger liver post- than pre-operatively.
Post-operative hepatic insufficiency was defined as a peak post-
operative bilirubin >50 mmol/l and a peak post-operative
PK(INR)  1.7.
The body mass index (BMI) was calculated as weight (kg)/
height (m2). In order to analyse if pre-operative liver volumes were
influenced by pre-operative chemotherapy, the formula by
Vauthey et al.32 based on body surface area (BSA) was used, where
BSA (cm2) = weight (kg)0.425 ¥ height (cm)0.725 ¥ 71.84.
Statistical analysis
Statistical analysis was performed using IBM SPSS Statistics
version 19 (IBM Corp., New York, NY, USA). Tests regarding
differences in %FLVpost/pre-op between groups were performed using
two-tailed independent sample t-tests. The %FLVpost/pre-op distribu-
tion was tested with the Shapiro–Wilk test, the result of which
indicated this variable is normally distributed. Otherwise, the
Mann–Whitney U-test was used to compare continuous data and
Fisher’s exact test was used for categorical data. P-values <0.05
were considered statistically significant. If not stated otherwise,
data are expressed as mean  standard error of the mean (SEM).
Results
Patient characteristics and peri-operative data are shown in
Table 1. The regimens used in the chemotherapy groups are
shown in Table 2. In Table 3, liver volumes before and after a
resection are shown for the two groups. A linear correlation was
found between regenerated volume, expressed as %FLVpost/pre-op
and the time interval between the end of chemotherapy to the
operation, as shown in Fig. 1. In Fig. 2, regenerated volumes as
functions of patient age are shown for both groups. No differences
between groups were found in the ratio of pre-operative FLV and
BSA (P = 0.80).
No difference in %FLVpost/pre-op was found between patients
treated with or without bevacizumab (88  6% versus 83  3%;
P = 0.43). Patients treated with adjuvant chemotherapy (n = 63)
had volumetric liver regeneration, %FLVpost/pre-op, equal to patients
not receiving adjuvant treatment (n = 11) (88  2% versus 87 
4%; P = 0.76).
Patients who underwent PVE and received pre-operative
chemotherapy (n = 9) versus patients receiving pre-operative
chemotherapy alone (n = 25) did not demonstrate any significant
difference in %FLVpost/pre-op (89  4% versus 82  4%; P = 0.22).
Patients suffering from post-operative hepatic insufficiency
(n = 13, of whom 5 patients were treated with preoperative
chemotherapy) demonstrated a significantly lower %FLVpost/pre-op
(79  3% versus 89  2%; P = 0.013) than patients with lower
levels of bilirubin and PK(INR) (n = 61).
Table 4 shows in-hospital morbidity after a resection graded
according to Dindo et al. 33 No difference in total morbidity was
found between the groups (P = 0.35). There was zero 90-day
mortality
Discussion
In this study, it was found that pre-operative chemotherapy before
a major liver resection results in diminished regenerated liver
volume. The impact of pre-operative chemotherapy on post-
resectional liver volume has previously only been investigated to a
limited extent. Tanaka et al.34 concluded that volumetric liver
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regeneration after mainly minor liver resections was unaffected by
pre-operative chemotherapy. The fact that only major liver resec-
tions were included in this study could account for this discrep-
ancy, as differences in regeneration are more likely to be displayed
if there is a greater total volume gain.35 In addition, the time
period from the last chemotherapy cycle to a resection, as shown
in this study to be of importance, was not reported in the study by
Tanaka et al. 34 As interest was in evaluating the final regenerative
response, it was choosen to compare liver volumes before a resec-
tion to the volumes attained 1 year after the resection, when the
regeneration process is completed.29
The influence of chemotherapy on liver regeneration has been
more thoroughly investigated in conjunction with portal vein
occlusion in preparation for major liver resection, where most
investigators have found no impact of chemotherapy36,37 although
reduced volumetric regeneration has been found with prolonged
chemotherapy.27,38 The time interval between the ending of
chemotherapy and portal vein occlusion has not been implicated
in reducing regeneration.39
The importance of chemotherapy-induced parenchymal
lesions on liver regeneration is yet unknown. As no investigation
regarding the histology of tumour-surrounding liver parenchyma
was made in this study, speculation about the possibility that
chemotherapy-treated patients with histopathological parenchy-
mal transformations also had impaired liver regeneration after
hepatectomy can only be made. Earlier studies have demonstrated
that chemotherapy-treated patients are at a risk of developing
pathological changes in their livers.23–25 It seems that many of these
lesions are reversible, as it has been shown that a correlation exists
between the presence of chemotherapy-induced lesions and the
interval between the cessation of chemotherapy and resection.40,41
Pre-operative chemotherapy increased post-operative morbidity
in the study by Nordlinger et al.,19 where a resection was per-
formed a median of 4 weeks after the last chemotherapy cycle.
Welsh et al.42 found that a prolonged time period from stopping
chemotherapy to a resection resulted in a reduction in surgical
complications although no influence on total morbidity was
found. It is conceivable that a reduced regenerative capacity of the
liver after neoadjuvant chemotherapy as found in this study is
Table 1 Patient characteristics and peri-operative data
No chemotherapy Chemotherapy P
No. of patients 40 34 –
Sex (male/female) 21:19 19:15 0.82
Age (years) 66 (46–86) 62 (42–74) 0.003
BMI (kg/m2) 26.5  0.8 24.0  0.4 0.010
No. of diabetes patients 6 4 0.75
Metastasis volume (ml) 66  18 29  9 0.08
No. of metastases 2 (0–5)* 2 (0–7)* 0.74
Size of largest metastasis (mm) 48 (0–120)* 25 (12–99)* 0.30
No. of patients with PVE 1 9 <0.0001
No. of chemotherapy cycles 7 (2–28)
Time to surgery after chemotherapy (days) 40 (20–88)
Type of resection (n)
Right-sided hepatectomy  atypical resection 26 21 0.18
Extended right-sided hepatectomy  atypical resection 5 8 0.10
Left-sided hepatectomy  atypical resection 9 5 0.30
Operative bleeding (ml) 700 (100–15000) 1000 (250–4000) 0.21
Length of hospital stay (days) 8 (5–79) 9 (5–19) 0.69
Peak post-operative bilirubin (mmol/l) 32 (12–202) 35 (13–127) 0.77
Peak postoperative PK(INR) 1.6 (0.9–2.1) 1.6 (1.1–2.6) 0.44
Time from operation to post-operative image (days) 326 (127–822) 315 (188–593) 0.45
Data are presented as either mean  standard error of the mean (SEM), or median (range). BMI, body mass index; PVE, portal vein embolization.
*Based on pathological-anatomic diagnosis.
Table 2 Chemotherapy regimen combinations
Chemotherapy regimen Number of
patients
5-FU + oxaliplatin 17
5-FU + oxaliplatin + bevacizumab 6
5-FU + oxaliplatin + panitumumab 2
5-FU + oxaliplatin followed by
5-FU + irinotecan
2
5-FU + irinotecan 4
5-FU + irinotecan + cetuximab 2
Other combination 1
5-FU, 5-fluorouracil.
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associated with an increased post-operative morbidity, although
no evidence of this could be found in the present small study.
No measurement of liver volumes before initiation of pre-
operative chemotherapy was made. To our knowledge, no inves-
tigation on the effect of chemotherapy on liver volume has been
made. However, the liver volume is proportional to the liver fat
content43 and chemotherapy has been implicated to cause hepatic
steatosis.23 There exists the possibility that patients treated with
pre-operative chemotherapy had an increased liver volume before
a hepatectomy. To investigate this, the ratio between the pre-
operative liver volume and BSA was calculated32 and no differ-
ences were found between the different study populations,
indicating that chemotherapy did not change the pre-operative
liver volume. The tumour volume in the non-chemotherapy
group was larger as compared with the group with chemotherapy
although not reaching statistical significance (Table 1). In the
context of portal vein occlusion in preparation for major liver
resection, it has previously been shown that a larger tumour
volume is associated with an increased volume of the future liver
remnant before any intervention.27 Because the tumour volumes
in the present study were relatively small and not significantly
different between groups, it is believed that this effect cannot
explain the difference in regeneration.
No statistical significant decrease in liver regeneration could be
found among patients who underwent PVE compared with
patients who did not. These findings match Van den Esschert
et al.44 who reported approximately the same degree of regenera-
tion for groups equivalent to the present.
In addition to the findings above, it was also found that patients
with a peak bilirubin >50 mmol/l and PK(INR)  1.7 post-
operatively had impaired volume regeneration suggesting a
link between post-operative hepatic insufficiency and final
Table 3 Liver volumes
No chemotherapy Chemotherapy P
FLV before resection (ml) 1521  50 1556  47 0.64
DFLV (ml) -135  35 -278  32 0.005
%FLVpost/pre-op 91  2 83  2 0.007
Data are presented as mean  standard error of the mean (SEM). Functional liver volume (FLV) signifies functional liver volume. DFLV denotes the
paired volume difference in FLV between after and before resection. %FLVpost/pre-op is defined as the ratio of post- and pre-operative FLV.
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Figure 1 Correlation between regenerated volume and the time
interval between cessation of chemotherapy and the operation. A
linear correlation was found (r = 0.37, P = 0.031)
1.4
0.5
0.6
0.7
0.8
0.9
1
1.1
1.2
1.3
40 45 50 55 60 65 70 75 80
Age (years)
85 90
%
F
LV
po
st
/p
re
-o
p
(a)
1.4
(b)
0.5
0.6
0.7
0.8
0.9
1
1.1
1.2
1.3
40 45 50 55 60 65 70 75 80
Age (years)
85 90
%
F
LV
po
st
/p
re
-o
p
Figure 2 Regenerated volume as a function of the patient's age for
groups without chemotherapy (a) and with chemotherapy (b). There
was a negative linear correlation between parameters in groups
(r = -0.36, P = 0.023 and r = -0.558, P = 0.0001, respectively)
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regenerated liver volume. This could indicate that the degree of
final liver regeneration is determined shortly after resection.
In this retrospective study, it was found that %FLVpost/pre-op was
on average 83% and 91% among patients treated with and
without pre-operative chemotherapy, respectively. The latter
number (91%) may seem high, but several previous studies45,46
have reported similar numbers. Lower numbers are being
reported as well, e.g. Nagino et al.31 reporting 74%. Although, in
this case, the low number may be explained by patients having
injured livers owing to obstructive jaundice, there are studies on
healthy livers reporting as low as 83%.30 The relatively large span
of reported percentages is hard to explain and remains to be
investigated further.
The limitations of this study include its retrospective design
with the inherent problem concerning comparison between
groups. For example, previous work show that a higher BMI34 and
age38 has been linked to weakened regenerative capacity. A nega-
tive effect on regeneration of increased age was also found in the
present study (Fig. 2). Both BMI and age were significantly lower
in the chemotherapy group. This may indicate that the effect of
pre-operative chemotherapy on volume regeneration was under-
estimated in this study. Another limitation is the relatively small
number of patients included, and the results require confirma-
tion. In addition, the regimens of chemotherapy were inhomoge-
neous although oxaliplatin-based chemotherapy was used in 25
out of 34 chemotherapy patients. The type of resection differed
somewhat between groups (Table 1), but as inclusion criteria a
‘major liver resection’ was choosen, defined as resection of 3 or
more Couinaud’s segments. In a living-donor hepatectomy there
does not seem to be any difference in regenerated volume between
right- and left-sided hemihepatectomies at 1-year follow-up,47 jus-
tifying the inclusion of different resections.
In this retrospective study volume regeneration was investi-
gated. There are some indications that functional regeneration
does not follow the volumetric regeneration.48 Some previous
studies have suggested that functional recovery after a partial
hepatectomy takes even longer than volume regeneration.30,46
Moreover biochemical markers for measuring liver function have
been proven insufficient. Shimizu et al.46 showed that functional
liver reserve measured with technetium-99 m-galactosyl human
serum albumin scintigraphy was lowered for an extended period
of time (>6 months). In the same study, full volumetric recovery
measured by CT was seen at the end of the first month post-
operatively. In future studies, in addition to image volume
measurements, it would be interesting to use methods for liver
function estimation in studying the effects of chemotherapy on
liver regeneration.
Conclusion
It is concluded that in this retrospective study, pre-operative
chemotherapy for colorectal liver metastases negatively affects
volume regeneration after a partial hepatectomy, the impact
being greater the sooner the resection is made after cessation of
chemotherapy.
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